Вісник проблем біології і медицини -2023 -Вип. 4 (171) / Bulletin of problems in biology and medicine -2023 -Issue 4 (171)171 КЛІНІЧНА ТА ЕКСПЕРИМЕНТАЛЬНА МЕДИЦИНА / CLINICAL AND EXPERIMENTAL MEDICINE and vitamin D, all patients were divided into 2 groups. Group 1 patients (n=24) received Creon 25,000 according to the scheme and vitamin D 4,000 IU/day during 12 weeks of antiviral therapy and 12 weeks after the end of antiviral therapy. Patients of group 2 (n=28) took only Creon 10000 according to the scheme. Quality of life was assessed using the SF-12 questionnaire, and situational anxiety was assessed using the Spielberger-Hanin method. Data analysis and processing were carried out in Jamovi 2.3.2.1, Microsoft Office Excel for Windows 2016 programs using the Mann-Whitney U-test, Wilcoxon, McNemar test. The difference was considered statistically significant at p<0.05.Results. As a result of complex therapy with the additional usage of vitamin D, sustained virological response (SVR) was achieved in 100% of patients in group 1 and only 82.1% of patients in group 2. After the treatment, a decrease in the frequency of complaints of diarrhea, constipation, flatulence, abdominal pain, itching, heaviness in the right hypochondrium, hepatomegaly, arthralgia, and myalgia was observed in all patients, with a significant preponderance in the group that additionally received vitamin D. After treatment patients of group 1 were less bothered by anxiety, increased fatigue, emotional lability, and significantly higher indicators of quality of life were found than patients of group 2.Conclusions. The inclusion of a polyenzyme drug with minimal lipase activity of 25,000 and vitamin D in a dose of 4,000 IU/day to the complex treatment of patients with CHC combined with CP increases the efficacy of antiviral therapy and leads to a marked regression of manifestations of hepatobiliary dysfunction, asthenovegetative and dyspeptic syndromes, thereby reducing situational anxiety and improves the quality of life of these patients.Key words: chronic hepatitis C, chronic pancreatitis, exocrine insufficiency of the pancreas, vitamin D, virological response, direct antiviral drugs ORCID and contributionship: Derbak M. A.: https://orcid.org/0000-0003-4791-4080 AEF Buchok O. V.: https://orcid.org/0000-0001-5502-5158 BCD Boldizhar O. O.: https://orcid.org/0000-0002-9553-5782 F Bletskan M. M.: https://orcid.org/0000-0002-8069-6145 BC Svistak V. V.: https://orcid.org/0000-0002-9552-6456 CD